It is also possible that the Allergan endpoint is understating the benefit because it doesn't properly account for reductions in severity.
From a patient-benefit perspective, the ideal measure is one that integrates severity over time. But that is hard to measure.
Incidentally, there is a group at Beth Israel in Boston that claims there is a significant difference in Botox effectiveness between patients that describe their headache pain as "imploding" (or a tight band) vs. "exploding." (They say it works for the imploders but not the exploders).
Market Data 
Markets 
AI
